Sure Dividend

This Health Care Dividend Aristocrat Will Profit From Old Age – Globally


The world is aging.  The average global population age is increasing.

Average Global Age
Source:  The Economist

This means there are more middle-aged and elderly people than ever before.  This trend is expected to continue far into the future.

Population Age Groups
Source:  The Wisdom Years

The older someone is, the more they spend on health care (on average).

Health Care Spending by Age
Source:  From Peterson-Kaiser Health System Tracker
Note:  Data for the United States, in 2012.

Demographic changes create opportunity.  What if you could benefit from these changes?

The business analyzed in this article will benefit from the coming demographic changes. Better yet, it already has a long history of success

… As evidenced by its 44 consecutive dividend increases.

It also is a timely buy.  It is ranked in The Top 10 using The 8 Rules of Dividend Investing.

The business I am talking about will benefit from both:

This article examines the investment opportunity at Abbott Labs (ABT).
Note:  I am personally long Abbott Labs.

Get to Know Abbott Labs

Abbott Labs was founded in 1888.  Today the company is a leader in several key categories

Abbott Labs Leadership
Source:  Abbott Labs JP Morgan Conference Presentation, slide 4

Abbott is the global leader in adult nutrition.  The company’s adult nutrition leadership is a result of its Ensure brand.

The company grew adult nutrition sales year-over-year by 5.2% in the United States and 3.6% internationally (constant-currency) in its most recent quarter.

The company’s adult nutrition category will continue to be boosted by favorable demographic trends going forward.

Abbott Labs is much more than adult nutrition and baby formula.  The company operates in 4 segments.

Each segment is shown below along with the percentage of total revenue generated for Abbott Laboratories in fiscal 2015:

The Nutrition segment’s primary brands are Ensure, Pedialyte, and Similac.

The established pharmaceutical segment is noteworthy for its geographical distribution.  It sells generic pharmaceuticals only outside the Untied States.  A full 75% of the segment’s revenue comes from key emerging markets.

But it’s not just the established pharmaceutical segment that has a large emerging market presence…

Abbott Labs Is An Emerging Market Business

Abbott Labs sales by country type (developed, emerging) are shown below:

The company generates half of its revenue in emerging markets.

It also generates half of its revenue in direct to consumer sales.  This means Abbott Labs health care products are popular with consumers, not just health care providers.

Demographic changes will be most impactful in emerging markets.

They have the fastest population growth.  More babies means more formula sales for Abbott.

Emerging markets will also make the biggest gains in life expectancy increases.  Emerging market population’s dwarf developed populations.  This means more sales for Abbott’s:

The company has positioned itself extremely well.  It is primed to take advantage of emerging market growth.

With Abbott Labs you get expert management and developed world regulation and transparency combined with emerging market exposure and growth.

Total Returns & Earnings-Per-Share Growth

What type of growth should Abbott Labs investors expect going forward?

I believe Abbott Labs investors should expect earnings-per-share growth of around 10% a year going forward.  The company’s growth will come from a mix of acquisitions, organic revenue growth, small margin improvements, and share repurchases.

This growth combined with the company’s current dividend yield of 2.7% gives Abbott Labs investors expected returns of 12% to 13% a year.

Recent Acquisitions Are A Potential Growth Catalyst

One of Abbott Lab’s growth strategies is acquisitions.

The company has recently engaged in 2 large acquisitions:

The Alere acquisition will boost Abbott Lab’s diagnostics segment.

The St. Jude Medical acquisition will bolster Abbott Lab’s medical devices segment.

Both acquisitions are expected to be accretive to earnings within the first full fiscal year after closing…  Which is good news for shareholders.

Abbott Labs will benefit from these acquisitions far into the future.  The company can integrate and roll out products from the respective acquired companies throughout the globe – this is the power of Abbott Lab’s international approach.

The St. Jude Medical acquisition is funded by a mix of cash and new share issuance.

I would have preferred Abbott Labs to take on additional debt rather than issue new shares to take advantage of historically low interest rates.  Still, both acquisitions will likely be beneficial for long-term shareholders.

Abbott Labs Scores High Marks for Safety & Stability

The health care sector has historically performed better than average during recessions.

You simply cannot cut back on baby formula or pharmaceuticals when times get tough.  This makes Abbott Labs recession resistant.

History has proven Abbott Labs handles recessions very well.  Abbott Labs is one of the 10 most recession proof Dividend Aristocrats.  It’s stock fell 5% in 2008…  While the S&P 500 declined 38%.

The company grew earnings-per-share (and dividends) each year through the Great Recession of 2007 to 2009.

Recession performance is only one aspect of the company’s safety.

Abbott Lab’s excellent dividend history speaks to its strength and safety:

It is highly likely the company’s dividend streak continues far into the future.  The company has a reasonable payout ratio of 50% (using adjusted earnings).

Abbott Lab’s balance sheet is also in good shape.  Through the 1st quarter of 2016, the company had about $4 billion in cash and $8 billion in debt on its books.  To put that in perspective, the company generates about $3 billion a year in cash from operations.

Abbott’s Compelling Price to Value Proposition

Abbott Labs has historically traded for around the same price-to-earnings multiple as the S&P 500 since the AbbVie spin-off in 2012.

I don’t believe Abbott Labs should trade for the same price-to-earnings multiple as the S&P 500…

The company is of a higher quality than the average S&P 500 stock.  It also has better total return prospects than the average S&P 500 stock.

The market disagrees at this time.  Abbott Labs’s price-to-earnings ratio has not followed suite with the S&P 500’s.

I believe Abbott Labs should trade at least in line with the S&P 500.  Relative to the market, Abbott Labs is significantly undervalued today.

Relative to its historical average price-to-earnings ratio, the company is likely trading around fair value.  Taken as a whole, I expect an investment in Abbott Labs to beat the S&P 500 Index over the next 5 to 10 year period.

Abbott Labs Is a Buy at Current Prices

Investors in Abbott Laboratories should expect total returns of around 12% to 13% a year going forward from dividends and earnings-per-share growth…

An investment that grows at 12% a year doubles in value about every 6 years.

The company scores high marks for safety and will very likely continue increasing dividend payments far into the future.

Additionally, Abbott Labs gives investors lower risk exposure to emerging markets.

The company currently ranks as a Top 10 dividend stock using The 8 Rule of Dividend Investing.

Abbott Labs ranks highly using The 8 Rules because it has:

I believe Abbott Labs is an excellent example of a high quality, shareholder friendly business trading at fair or better prices now.

Investors looking for exposure to the health care sector and/or emerging markets should look no further than Abbott Labs.

Want more high quality health care stocks?  Click here to download a data-filled spreadsheet of all 13 health care sector stocks with 25+ years of dividend payments – ranked in order using The 8 Rules of Dividend Investing.




Click Here To See All Articles